Evidence-Based Guide

Male Pattern Hair Loss

A physician's evidence-based guide to androgenetic alopecia: finasteride, minoxidil (topical and oral), dutasteride, combination therapy, and what actually works in 2026.

What is the best treatment for male pattern hair loss in 2026?

For most men with androgenetic alopecia (male pattern hair loss), the best-supported medicines are oral finasteride 1 mg daily, which is FDA-approved for male pattern hair loss, and topical minoxidil 5% twice daily (finasteride prescribing information; minoxidil 5% Drug Facts label). European evidence-based guidelines recommend both, as summarized in a phase III trial report (Piraccini 2022). In a meta-analysis of five randomized trials, using them together gave better global photographic scores than either drug alone, with similar side effects, although the change in hair density did not differ significantly (Chen 2020). Low-dose oral minoxidil (usual starting dose 1 to 5 mg daily in men) lacks FDA approval for hair loss but has been reported as an effective, well-tolerated alternative for healthy patients having difficulty with topical minoxidil (Skin Appendage Disord 2023 review; Randolph 2021). Finasteride usually needs three months or more of daily use before benefit is seen, and stopping it reverses the effect within 12 months. A licensed clinician, accessible via telehealth, can start finasteride and minoxidil after reviewing medical history.
Medically reviewed by Parth Bhavsar, MD. Updated July 18, 2026.

Key Takeaways

  • Male pattern hair loss is the most common hair loss disorder; its frequency increases with age, and it affects up to 80% of Caucasian men.[1] It is caused by androgen-dependent miniaturization of scalp hair follicles, with scalp dihydrotestosterone (DHT) implicated as a contributing cause.[2]
  • Oral finasteride 1 mg is FDA-approved for male pattern hair loss, and 5% topical minoxidil is sold over the counter for men.[15][16] Oral minoxidil is not FDA-approved for hair loss and is used off-label.[19] Finasteride usually needs three months or more of daily use before benefit is seen; minoxidil results may appear at 2 months, though some men need at least 4 months.[15][16]
  • Combination therapy outperforms monotherapy on photographic assessment. In a meta-analysis of five randomized trials, finasteride plus topical minoxidil gave better global photographic scores and more men with marked improvement than either drug alone, with similar adverse events.[3]
  • Low-dose oral minoxidil is an off-label option that lacks FDA approval for hair loss.[11] In a 24-week single-arm study of 30 men taking 5 mg daily, hair counts rose significantly, while hypertrichosis occurred in 93% and pedal edema in 10%.[4]
  • Dutasteride 0.5 mg (off-label for hair loss in the US, approved for male androgenetic alopecia in Japan and South Korea) inhibits both type I and type II 5-alpha reductase and suppresses DHT more than finasteride.[19] A small single-arm study suggests it may help some men who did not respond to finasteride.[6]
  • Sexual side effects with finasteride were uncommon in trials (about 1 to 2 percent, slightly above placebo) and resolved in men who stopped and in most who continued. The label also lists postmarketing reports of sexual dysfunction that continued after stopping.[15]
  • Discontinuation reverses effects. Stopping finasteride reverses its effect within 12 months, and topical minoxidil must be continued to keep regrowth. Ongoing therapy is required to maintain results.[15][16]
Editorial medical illustration representing Male Pattern Hair Loss
Male pattern hair loss: an evidence-based overview from the TeleDirectMD medical team.

Male pattern hair loss, medically known as androgenetic alopecia, is the most common cause of hair loss in men, driven by a genetically determined sensitivity of scalp follicles to dihydrotestosterone (DHT). This guide is a physician's evidence-based look at how finasteride, topical and oral minoxidil, and dutasteride actually work, what combination therapy adds, how platelet-rich plasma and hair transplantation fit into the picture, and what does not work, in 2026. Key claims are cited to the numbered sources listed at the end.

What Is Male Pattern Hair Loss?

Male pattern hair loss, medically termed androgenetic alopecia, is the progressive thinning of scalp hair that follows a predictable pattern driven by genetics and androgen hormones. It is the most common hair loss disorder; its first signs usually appear in the teenage years, and its frequency increases with age, affecting up to 80% of Caucasian men.[1] Unlike diffuse hair thinning from illness, nutritional deficiency, or telogen effluvium, male pattern hair loss follows a specific, recognizable distribution: recession at the temples, thinning at the crown (vertex), or both, while hair at the back and sides of the scalp is typically spared.

Androgenetic alopecia and DHT

The driving mechanism is dihydrotestosterone (DHT), a potent androgen derived from testosterone via the enzyme 5-alpha reductase. Scalp hair follicles in genetically susceptible men carry androgen receptors that are unusually sensitive to DHT. In the frontal and vertex scalp of susceptible men, follicles progressively shrink, a process described as androgen-dependent miniaturization, with scalp DHT implicated as a contributing cause.[2] Follicles at the occiput (back of the scalp) and temples along the sides carry fewer DHT-sensitive receptors, which is why donor hair from these zones remains viable for a lifetime and forms the basis of hair transplantation.

Genetics determine both the degree of follicular sensitivity to DHT and the age of onset. The condition is polygenic, meaning multiple genes contribute, and inheritance can come from either the maternal or paternal side, contrary to the popular belief that hair loss is inherited only through the mother's family.

Norwood-Hamilton pattern classification

The Norwood-Hamilton scale, which Norwood published in 1975 as a reproducible classification of male pattern baldness,[20] is used to grade male pattern hair loss in clinical trials,[4][9] running from stage I (no visible loss) through stage VII (extensive baldness with only a band of hair remaining at the sides and back). Stages II and III typically present as temporal recession, forming the classic "widow's peak" or receding hairline. Stage III vertex adds crown thinning to temporal recession. Stages IV through VII represent progressively larger areas of frontal and crown involvement, eventually merging into a single bald area separated from the sides only by a horseshoe-shaped fringe. Staging matters clinically because it informs both prognosis and treatment selection, discussed further in the decision framework below.

Norwood-Hamilton scale of male pattern hair loss: five key stages (I, II, III, IV, VI) illustrated as top-down views of the scalp showing progression from full coverage to horseshoe-pattern baldness
Five key stages of the Norwood-Hamilton scale. Stage I: no visible loss. Stage II: slight temporal recession. Stage III: pronounced M-shaped frontal recession. Stage IV: deep frontal recession plus crown thinning. Stage VI: extensive baldness merging frontal and crown, with only a U-shaped horseshoe band of hair remaining.

The Hair Growth Cycle: How DHT Disrupts It

The anagen, catagen, telogen cycle

Every scalp hair follicle cycles through three phases. Anagen is the active growth phase, lasting 2 to 7 years and determining how long hair can grow before it sheds. Catagen is a brief transitional phase, lasting 2 to 3 weeks, during which the follicle regresses. Telogen is the resting phase, lasting roughly 3 months, after which the hair sheds and a new anagen phase begins. At any given time, about 85 to 90 percent of scalp follicles are in anagen and 10 to 15 percent are in telogen, which is why losing 50 to 100 hairs a day is entirely normal.

Follicle miniaturization

In androgenetic alopecia, DHT progressively shortens the anagen phase with each successive cycle while the telogen phase stays roughly the same length or lengthens slightly. Over repeated cycles, this shifts the ratio toward more resting follicles and less active growth time per cycle. The follicle itself also physically shrinks, a process described as androgen-dependent miniaturization,[2] producing thinner, shorter, lighter-colored (less pigmented) hairs called vellus-like hairs in place of the thick, pigmented terminal hairs the follicle once produced. This is why male pattern hair loss looks like gradual thinning rather than sudden patchy loss. The follicles are not dying outright, at least not early on, they are shrinking and producing progressively weaker hairs until, eventually, some stop producing visible hair altogether.

This mechanism has a direct treatment implication: because miniaturization is at least partly reversible in its earlier stages, treatments that block DHT (finasteride, dutasteride) or that extend anagen and improve follicular blood flow (minoxidil) can partially reverse miniaturization and restore some terminal hair growth, but only in follicles that have not yet been miniaturized beyond the point of recovery. This is also why earlier treatment tends to produce better results than treatment started after years of untreated progression.

What's Changed in 2024 to 2026

Male pattern hair loss management has moved meaningfully in the past two to three years, with growing mainstream acceptance of a previously niche approach and incremental progress on the drug pipeline.

More data on low-dose oral minoxidil. Low-dose oral minoxidil has been proposed as an alternative for people who struggle with topical minoxidil. A review of 17 studies with 634 patients concluded that it was an effective and well-tolerated alternative for healthy patients having difficulty with topical formulations, while calling for larger randomized studies.[5] A retrospective multicenter study of 1,404 patients reported a good safety profile, with only 1.7% stopping because of adverse effects.[10] It still lacks FDA approval for hair loss.[11]

Topical finasteride phase 3 completion. A phase 3, randomized, controlled trial of a topical finasteride spray solution reported efficacy comparable to oral finasteride with substantially lower systemic absorption, and therefore a theoretically lower risk of systemic sexual side effects.[9] Topical finasteride is not yet FDA-approved as a standalone product in the US but is available through compounding pharmacies and has grown in popularity among men specifically trying to minimize systemic exposure.

Emerging: prostaglandin D2 antagonists and PP-405. Prostaglandin D2 (PGD2) has been identified as a mediator that inhibits hair growth in balding scalp, and PGD2 receptor antagonists are in early clinical development as a novel, non-hormonal mechanism distinct from DHT blockade. Separately, PP-405, a small molecule that activates a metabolic pathway to stimulate hair follicle stem cells, has entered early-phase trials. Neither is FDA-approved as of 2026, and patients should be cautious of any product marketed based on these mechanisms outside of a registered clinical trial.

Taken together, the treatment ladder has not fundamentally changed, finasteride and topical minoxidil remain first-line, but oral minoxidil has moved from a niche option to a mainstream alternative or add-on, and the pipeline for genuinely new mechanisms remains early-stage.

Decision Framework: How to Choose a Treatment

Treatment choice depends on Norwood-Hamilton stage, tolerance for oral versus topical medication, cost, and how a patient weighs efficacy against side-effect risk. The table below is this guide's general framework for matching stage to treatment; it is not taken from a published guideline table, and individual plans vary.

Norwood ScaleDescriptionBest treatment approach
IAdolescent hairline, no lossNo treatment needed
IISlight recession at templesConsider early finasteride if progressive
IIIDeeper temporal recession (widow's peak)Finasteride + topical minoxidil
III vertexRecession + crown thinningCombination therapy; monitor at 6 months
IVFrontal recession + notable crown lossCombination therapy; consider dutasteride if inadequate response
VBroader baldness with bridge of hairCombination therapy; hair transplant candidate
VI to VIIExtensive baldnessCombination therapy; hair transplant is primary option

Two principles guide almost every decision within this framework. First, earlier treatment produces better results, because follicles that have not yet miniaturized beyond a certain point are more responsive to DHT blockade and minoxidil than follicles that have been shrinking for years. Second, combination therapy is the standard of care for any stage beyond the earliest recession, not an escalation reserved for treatment failures.

Combination is standard, not monotherapy

For most men beyond the earliest stages of recession, this guide favors starting finasteride and topical minoxidil together rather than trying one, waiting months, and adding the other later. In a meta-analysis of five randomized trials, the combination gave higher global photographic scores, more men with marked improvement, and fewer men with no change or worsening than either drug alone; differences in hair density change and adverse events were not significant.[3]

Side effect frequency by medication

Side effectFinasteride 1 mgTopical minoxidil 5%Low-dose oral minoxidil
Decreased libido1.8% (placebo 1.3%)Not listedNot listed
Erectile dysfunction1.3% (placebo 0.7%)Not listedNot listed
Ejaculation disorder1.2% (placebo 0.7%)Not listedNot listed
Scalp irritation or itchingNot listedMore common with 5% than 2%; stop if irritation or redness occursNot listed
Facial or body hair growth (hypertrichosis)Not listedStop if unwanted facial hair growth occurs15.1% in a 1,404-patient cohort; 93% at 5 mg in 30 men
Early increase in sheddingNot listedCan occur; reflects hair-cycle synchronizationNot quantified
Fluid retention or edemaNot listedStop if hands or feet swell1.3% fluid retention in the cohort; 10% pedal edema at 5 mg
Lightheadedness or fast heartbeatNot listedStop if chest pain, rapid heartbeat, faintness, or dizziness occursLightheadedness 1.7%, tachycardia 0.9% in the cohort

Finasteride figures are year-1 trial rates from its prescribing information.[15] Topical minoxidil entries come from its Drug Facts label,[16] the 5% versus 2% trial[8] and a minoxidil review.[12] Oral minoxidil figures come from a 1,404-patient cohort[10] and a 30-man 5 mg study.[4] "Not listed" means the cited source gives no figure for that effect, not that it never occurs.

Finasteride: The First-Line Standard

How finasteride works

Finasteride is a selective inhibitor of type II 5-alpha reductase, the enzyme that converts testosterone to DHT. By blocking this conversion, finasteride decreases serum and scalp DHT,[2] with serum DHT suppression reaching 65% within 24 hours of a 1 mg tablet.[15] It does not regrow hair in follicles that have already been permanently lost (no visible follicle remaining), but it can restore terminal hair production in follicles that are miniaturized but still viable, and it reliably slows or halts further progression in the majority of men who take it consistently.

Efficacy: long-term data

In two 1-year placebo-controlled trials of 1,553 men aged 18 to 41, with 1,215 continuing into blinded second-year extensions, finasteride 1 mg improved scalp hair by every evaluation method at 1 and 2 years, while men on placebo continued to lose hair.[2] An independent panel reviewing photographs rated 48% of men on finasteride as having increased hair growth at 12 months and 66% at 2 years, compared with 7% on placebo.[15] Over 5 years, hair count in the finasteride group stayed above baseline,[15] and finasteride led to a 93% decrease relative to placebo in the 5-year likelihood of developing further visible hair loss.[7]

Side effects: what's real and what's rare

Finasteride's most discussed side effects are sexual. In the first year of the hair loss trials, decreased libido occurred in 1.8 percent of men on finasteride versus 1.3 percent on placebo, erectile dysfunction in 1.3 versus 0.7 percent, and ejaculation disorder in 1.2 versus 0.7 percent; these resolved in men who stopped treatment because of them and in most of those who continued.[15] Reports received after approval also include breast tenderness and enlargement, and depression, suicidal ideation and behavior; these come from postmarketing reports rather than the controlled trials.[15]

Post-finasteride syndrome: what the evidence shows

A subset of men report persistent sexual, neurological, or psychological symptoms that continue after stopping finasteride, sometimes termed post-finasteride syndrome. This remains a contested area. A 2020 review notes that the medical community has yet to recognize the syndrome, that there are no evidence-based effective treatments, and that many clinical studies assessed adverse events incompletely; its author nonetheless concludes that finasteride and dutasteride induce persistent sexual, neurological and physical side effects in a subset of men.[14] The finasteride label lists postmarketing reports of sexual dysfunction that continued after treatment was stopped.[15] The cited sources do not establish how often this happens, and any patient considering finasteride deserves a candid conversation about this uncertainty rather than either reassurance that it is impossible or alarm that it is common.

Topical Minoxidil: The OTC Foundation

5% vs 2% concentration

Minoxidil was originally developed as an oral antihypertensive; hair growth was an incidental effect discovered during use, which led to development of the topical formulation for androgenetic alopecia. Topical minoxidil is available over the counter in 2% and 5% solutions, plus a 5% foam. A randomized trial comparing the two concentrations directly found 5% minoxidil produced significantly greater hair count increase than 2% minoxidil, with both outperforming placebo, at the cost of a modestly higher rate of local scalp irritation with the 5% formulation.[8] The 5% concentration is now the standard recommendation for men; the 2% formulation is largely retained for use in women, in whom higher concentrations more often cause unwanted facial hypertrichosis.

Application protocol

Standard dosing is 1 mL applied directly to the affected scalp twice daily, and the label notes that using more or more often will not improve results.[16] Apply it morning and evening, massaged in and left to dry before styling products or lying down on a pillow. Consistency matters more than almost any other variable in topical minoxidil's real-world effectiveness: because its mechanism (discussed below) depends on maintaining local drug levels, missed applications reduce the benefit disproportionately relative to how minor a missed dose might seem.

The transient dread shed

Some men notice an increase in shedding after starting minoxidil, colloquially called the "dread shed." Minoxidil can cause resting (telogen) follicles to shed, usually soon to be replaced by new, thicker hairs in a new growth (anagen) phase; the increased hair loss reflects the synchronization of the hair cycle that treatment induces.[12][4] This shed is not, by itself, a sign of treatment failure. Setting this expectation before starting treatment can help men avoid stopping minoxidil prematurely.

What to expect on hair loss treatment Illustrative schematic only, not plotted from trial data. Month 0 Mo 1 Mo 3 Mo 6 Mo 9 Mo 12 Mo 18 Mo 24 Dread shed (transient) Hair density (efficacy) Time on daily therapy (months) Relative intensity (arbitrary units) Schematic; see caption for sourced timing
What to expect on hair loss treatment (schematic, not trial data). Finasteride usually needs three months or more of daily use before benefit is seen,[15] minoxidil results may appear at 2 months though some men need at least 4 months,[16] and in the finasteride trials hair growth improved at both 1 and 2 years.[2]
Discontinuation reverses gains

Hair regained with finasteride or topical minoxidil is maintained only with continued use. Withdrawal of finasteride leads to reversal of its effect within 12 months,[15] and the minoxidil label says continued use is necessary to keep regrowth, or hair loss will begin again.[16] Measurable changes from minoxidil disappear within months after it is stopped.[12] Patients should understand this before starting: these are maintenance therapies, not one-time cures.

Oral Minoxidil (Low-Dose): The Emerging Option

Why oral minoxidil for hair loss

Oral minoxidil at low doses has been proposed as an alternative for people who find topical minoxidil hard to use; many patients are poorly compliant with topical minoxidil because of twice-daily application, undesirable hair texture, and scalp irritation. A review of 17 studies with 634 patients concluded that oral minoxidil was an effective and well-tolerated alternative for healthy patients having difficulty with topical formulations.[5]

Dosing: 0.25 to 5 mg daily

Low doses of oral minoxidil used for alopecia range from 0.25 to 5 mg once daily, well below the standard 10 to 40 mg used for severe and uncontrolled hypertension.[4] A 2023 review gives a usual starting dose of 1 to 5 mg daily for men with androgenetic alopecia and a maximum of generally 5 mg daily, with the dose increased gradually only if the patient responds well without major side effects.[11] An open-label, single-arm study of 5 mg once daily in 30 men found significant increases in hair counts at 12 and 24 weeks and vertex improvement on expert photographic review in all patients, with a good safety profile in healthy subjects; it had no control group. Its authors recommend taking the first dose at bedtime to avoid orthostatic hypotension.[4]

Side effects: hypertrichosis, transient edema

The most common side effect is hypertrichosis, increased fine hair growth on the face and body. In a retrospective multicenter study of 1,404 patients (two-thirds of them women) taking low-dose oral minoxidil, it occurred in 15.1% and led to stopping treatment in 0.5%,[10] while in the 30-man study at 5 mg daily it occurred in 93%.[4] Women are more prone to hypertrichosis than men.[11] Fluid retention occurred in 1.3% of the larger cohort,[10] and pedal edema in 10% of men in the 5 mg study, appearing at 1 to 2 months and resolving spontaneously after 2 to 3 months.[4] With topical minoxidil, the most common adverse reactions are irritant and allergic contact dermatitis on the scalp.[12]

Cardiovascular considerations

Oral minoxidil's only FDA-labeled use is hypertension, at much higher doses, and that label carries a boxed warning that it can cause pericardial effusion, occasionally progressing to tamponade, and that angina may be exacerbated.[17] At low doses for hair loss, systemic adverse effects were infrequent in the 1,404-patient cohort: lightheadedness 1.7%, fluid retention 1.3% and tachycardia 0.9%, with no life-threatening adverse effects.[10] A 2023 review classes hypertrichosis and cardiovascular symptoms as dose-dependent side effects and pericardial effusion as an idiosyncratic one.[11] The authors of the 5 mg study recommend not prescribing oral minoxidil to elderly patients with an increased risk of myocardial infarction, heart failure, chronic renal failure, or severe hypertension, and say it should be considered only in healthy subjects.[4] It is not a decision to make casually for a cosmetic indication without at least a basic cardiovascular history.

Dutasteride: The Stronger 5-Alpha Reductase Inhibitor

Dutasteride inhibits both type 1 and type 2 5-alpha reductase isoenzymes,[18] compared with finasteride's type II inhibition, and suppresses DHT in serum and scalp more than finasteride does.[19] At 0.5 mg daily, median serum DHT fell by 85% after 1 week and 90% after 2 weeks.[18] In the United States it is indicated for benign prostatic hyperplasia, not hair loss,[18] and it is used off-label for hair loss; Japan and South Korea have approved oral dutasteride 0.5 mg daily for male androgenetic alopecia.[19]

An uncontrolled, single-arm study of 35 Korean men who had not improved after at least six months of finasteride 1 mg daily found that, of the 31 who completed six months of dutasteride 0.5 mg daily, 24 (77.4%) improved on global photographs and hair density rose by 10.3%; transient sexual dysfunction occurred in six patients (17.1%).[6] Without a control group, this suggests rather than proves that dutasteride helps some finasteride non-responders. Because dutasteride has a much longer half-life than finasteride (about 5 weeks versus about 4.5 hours),[19] any side effects, sexual or otherwise, may also take longer to resolve after discontinuation, which is a relevant consideration when counseling patients before they start. Notably, 5-alpha reductase inhibitors are not limited to men: case data in postmenopausal women with patterned hair loss and normal androgen levels has also shown a response to finasteride, underscoring that the DHT pathway, while central to male pattern hair loss, is not exclusively a male phenomenon.[13]

Combination Therapy: When One Isn't Enough

Because finasteride (or dutasteride) and minoxidil act through different mechanisms, DHT suppression versus direct stimulation of follicular growth, combining them is expected to add benefit rather than duplicate it. A meta-analysis of five randomized trials supports this on photographic outcomes: the combination had significantly higher global photographic scores, more patients with marked improvement, and fewer with no change or deterioration than either drug alone, but no significant difference in hair density change, and similar adverse events. Only two of the five trials compared the combination with finasteride alone.[3]

MedicationRouteTypical doseTime to visible effectWhat the cited evidence shows2026 monthly costPrescription needed?
FinasterideOral1 mg dailyUsually 3 months or more[15]Increased hair growth on photo review in 48% vs 7% on placebo at 12 months[15]$10 to $30 genericYes
Topical minoxidil 5%Topical1 mL twice daily[16]May occur at 2 months; some men need 4 months[16]More regrowth than 2% and placebo at 48 weeks[8]$15 to $30 (OTC)No
Oral minoxidil (low-dose)OralUsual start 1 to 5 mg daily; maximum generally 5 mg[11]Hair counts up at 12 weeks in a 5 mg study[4]All 30 men improved on vertex photo review; single-arm, no control[4]$10 to $30 genericYes (off-label)
DutasterideOral0.5 mg dailyAssessed at 6 months in finasteride non-responders[6]24 of 31 men (77.4%) improved on photos; single-arm, no control[6]$20 to $40 genericYes (off-label in US)
Finasteride + topical minoxidilCombinationPer abovePer individual drugsBetter photo scores than either drug alone in a meta-analysis of 5 trials[3]$25 to $60 combinedYes (finasteride)
Topical finasterideTopical0.25% spray, 50 to 200 µL once daily[9]Hair count up vs placebo at 12 weeks[9]Hair count gain similar to oral finasteride at 24 weeks[9]$50 to $80 compoundedYes (compounded)
Finasteride 1 mg vs placebo: photo panel ratings % of men rated by an independent panel as having increased hair growth on photographs 0% 25% 50% 75% 100% Finasteride 1 mg, 12 months Finasteride label, clinical studies 48% Placebo, 12 months Finasteride label, clinical studies 7% Finasteride 1 mg, 2 years Finasteride label, clinical studies 66% Placebo, 2 years Finasteride label, clinical studies 7% % of men with increased hair growth on expert photographic review
Share of men rated by an independent photo panel as having increased hair growth on finasteride 1 mg versus placebo in the pivotal trials. Comparable responder rates for the other treatments are not available from the cited sources.[15]

Some men substitute low-dose oral minoxidil for the topical formulation within this combination, pairing it with finasteride or dutasteride, trading the inconvenience of twice-daily topical application for the systemic side-effect profile of an oral vasodilator. Either combination (oral 5-alpha reductase inhibitor plus topical minoxidil, or oral 5-alpha reductase inhibitor plus low-dose oral minoxidil) is reasonable; the choice generally comes down to which side-effect profile and dosing routine a given patient prefers.

Platelet-Rich Plasma (PRP) and Adjuncts

PRP evidence

Platelet-rich plasma involves drawing a patient's own blood, concentrating the platelet-rich fraction by centrifugation, and injecting it into the scalp, on the theory that growth factors released by activated platelets stimulate follicular stem cells and improve local blood supply. Evidence quality varies considerably across studies, with meaningful differences in preparation protocols, injection technique, and number of sessions between trials, making cross-study comparison difficult. Where benefit is seen, it is generally modest and works best as an adjunct to finasteride and minoxidil rather than a standalone therapy. PRP typically requires a series of 3 to 6 monthly sessions followed by maintenance treatments, at a cash cost of several hundred dollars per session, which is a meaningful factor in whether it is a reasonable addition for a given patient.

Low-level laser therapy

Low-level laser therapy (LLLT) devices, available as combs, helmets, and caps, are FDA-cleared for androgenetic alopecia based on modest improvements in hair density in clinical trials, thought to work through photobiomodulation effects on follicular mitochondrial activity. Effect sizes are generally smaller than finasteride or minoxidil, and LLLT is best considered a low-risk adjunct rather than a primary treatment.

Microneedling

Microneedling, creating controlled microscopic injury to the scalp with a fine-needle roller or pen device, is theorized to stimulate wound-healing growth factor release and may improve topical minoxidil penetration when combined with it. Small trials suggest a modest additive benefit when microneedling is combined with topical minoxidil compared with minoxidil alone, though study sizes are small and protocols vary.

Hair Transplantation: When Medical Therapy Isn't Enough

FUE vs FUT

Hair transplantation relocates follicles from DHT-resistant donor zones (typically the back and sides of the scalp) to balding areas. Follicular unit extraction (FUE) removes individual follicular units directly with a small punch tool, leaving small scattered scars rather than a single linear scar. Follicular unit transplantation (FUT), the older strip method, removes a strip of donor scalp and dissects it into individual grafts under magnification, leaving a single linear donor scar but often allowing a greater total graft yield in a single session. Both are legitimate techniques; the choice often comes down to donor scar preference, total grafts needed, and surgeon expertise.

When to consider

Transplantation is a reasonable option for men with stable, well-defined areas of loss (typically Norwood IV and beyond) who have realistic expectations about donor supply limitations, and it works best in conjunction with, not instead of, ongoing medical therapy. Transplanted hair is DHT-resistant because it retains the biology of its donor site, but the native, non-transplanted hair surrounding a transplant remains susceptible to ongoing DHT-driven loss unless medical therapy continues. Skipping medical therapy after a transplant risks an uneven, patchy result over time as untreated native hair around the graft continues to thin.

Cost and expectations

Cost varies widely by geography, technique, and number of grafts, generally ranging from several thousand to well over ten thousand dollars for larger sessions. Full results take 9 to 12 months to mature, since transplanted follicles go through a shedding phase (similar in concept, though unrelated in cause, to the minoxidil dread shed) before regrowing in their new location. Realistic candidacy assessment, adequate donor density, appropriate expectations about graft survival, and commitment to continued medical therapy, matters more to a good long-term outcome than the specific technique chosen.

Hair loss treatment cost (2026 USD) Monthly out-of-pocket at typical US pharmacies with common discount cards. $0 $50 $100 $150 $200+ Finasteride 1 mg generic Prescription, oral $15/mo Topical minoxidil 5% (generic) OTC, twice daily $18/mo Oral minoxidil 2.5 mg generic Off-label prescription $15/mo Dutasteride 0.5 mg (off-label) Off-label prescription $25/mo Topical finasteride (compounded) Compounded prescription $65/mo PRP (in-office, per session) Every 3-6 months; not covered $600 Hair transplant (one-time) Range $4,000-$15,000; one-time $9000 Monthly out-of-pocket cost (US dollars)
Monthly out-of-pocket cost for hair loss treatments in 2026. Generic finasteride and topical minoxidil are the most cost-effective, running $10 to $30 per month.

Contraindications and Safety

Finasteride and pregnancy: never touch broken pills

Finasteride is contraindicated in women when they are or may potentially be pregnant, and women who are pregnant or may potentially be pregnant should not handle crushed or broken finasteride tablets because of the possibility of absorption and the potential risk to a male fetus. The tablets are coated and prevent contact with the active ingredient during normal handling, provided they have not been broken or crushed.[15] This should be discussed clearly with any patient whose household includes a partner who is or might become pregnant.

Pregnancy warning: broken pills

Women who are pregnant or may become pregnant should not handle broken or crushed finasteride tablets,[15] and should not handle dutasteride capsules.[18] Absorption carries a potential risk to a male fetus. Intact, coated finasteride tablets prevent contact with the active ingredient during normal handling.[15]

Minoxidil cardiovascular precautions

Topical minoxidil was well tolerated without evidence of systemic effects in a 48-week trial,[8] but its Drug Facts label says to ask a doctor before use if you have heart disease, and to stop and ask a doctor if chest pain, rapid heartbeat, faintness, dizziness, sudden unexplained weight gain, or swelling of the hands or feet occurs.[16] Oral minoxidil carries more meaningful cardiovascular considerations given its systemic vasodilating effect, discussed above, including a boxed warning on its hypertension label about pericardial effusion and worsening angina,[17] and the authors of the 5 mg hair loss study advise considering it only in healthy subjects.[4]

Drug interactions

Both finasteride and dutasteride lower prostate-specific antigen (PSA), which matters for any man undergoing prostate cancer screening. In the finasteride 1 mg trials, mean PSA fell from 0.7 to 0.5 ng/mL at 12 months, and the label says any confirmed increase from the lowest PSA value on treatment may signal prostate cancer.[15] Dutasteride reduced PSA by approximately 50% within 3 to 6 months, and its label says an isolated PSA value should be doubled for comparison with normal values in untreated men.[18] Oral minoxidil should be used cautiously alongside other antihypertensive medications, given additive blood pressure-lowering effects, and its label warns that giving it to patients already receiving guanethidine can result in profound orthostatic effects.[17]

What Doesn't Work: Supplements, "Hair Growth Shampoos," and Marketing Claims

The hair loss market is heavily populated with products that have little to no supporting evidence, and separating them from evidence-based treatment matters both for outcomes and for a patient's wallet.

  • Biotin supplements: effective only for the rare patient with an actual biotin deficiency, which is uncommon in men eating a normal diet; there is no credible evidence biotin regrows hair in men with normal biotin levels and androgenetic alopecia
  • "Hair growth" shampoos and topical cosmetic serums (non-minoxidil): may improve hair's cosmetic appearance (shine, thickness of the shaft) but do not affect the underlying miniaturization process driving androgenetic alopecia
  • Saw palmetto: has weak, inconsistent evidence for a mild 5-alpha reductase inhibiting effect; any benefit is substantially smaller than finasteride or dutasteride and should not be relied on as a primary treatment
  • Ketoconazole shampoo: may offer a small adjunctive benefit, possibly through mild anti-androgenic and anti-inflammatory scalp effects, but has not been shown to be an effective standalone treatment
  • Essential oils and scalp massage devices marketed for hair regrowth: lack rigorous trial evidence; scalp massage alone has weak evidence for small effects and is not a substitute for medical therapy
  • "Clinically proven" over-the-counter products without FDA-reviewed minoxidil: often rely on marketing language borrowing credibility from minoxidil's actual evidence base without containing an active ingredient with comparable data

The pattern across nearly all of these is the same: plausible-sounding mechanism, weak or absent trial evidence, and a price point that assumes the buyer will not ask for the data. Finasteride, minoxidil (topical or oral), and dutasteride have decades of trial evidence behind them and, notably, are also among the least expensive options on this list.

Red Flags: When Hair Loss Is Not Male Pattern

Most hair thinning in adult men is androgenetic alopecia, but certain presentations should prompt evaluation for an alternative diagnosis before defaulting to a male pattern hair loss treatment plan:

  • Patchy, well-circumscribed bald spots rather than diffuse thinning at the temples and crown, which suggests alopecia areata, an autoimmune condition with a different treatment approach entirely
  • Scalp itching, burning, scaling, redness, or pustules at the site of hair loss, which suggests an inflammatory or infectious scalp condition (seborrheic dermatitis, tinea capitis, folliculitis, or a scarring alopecia) requiring dermatologic evaluation and possibly biopsy
  • Rapid, diffuse shedding over weeks rather than gradual thinning over years, which is more consistent with telogen effluvium, often triggered by illness, surgery, significant weight loss, medication changes, or major stress 2 to 3 months prior
  • Hair loss with systemic symptoms such as fatigue, weight change, or menstrual irregularity in a partner (if evaluating for a family or genetic pattern), which can suggest thyroid disease or another endocrine cause worth screening for
  • Hair loss beginning before puberty or an unusual pattern (eyebrows, eyelashes, body hair) alongside scalp loss, which warrants evaluation for a different underlying cause
  • Scarring or shiny, smooth patches of scalp skin where hair once was, which suggests a scarring (cicatricial) alopecia and is a dermatologic urgency, since scarring alopecias cause permanent follicle destruction and benefit most from early treatment

Androgenetic alopecia has a hallmark pattern (temporal recession and/or crown thinning, gradual onset over years, family history, no associated scalp inflammation or systemic symptoms) that most experienced clinicians can recognize on a good history and scalp exam alone. Any significant deviation from that pattern is reason to pursue a broader diagnostic evaluation rather than starting finasteride and minoxidil by default.

Frequently Asked Questions

Yes. Finasteride 1 mg daily blocks the enzyme that converts testosterone to DHT.[2] In its pivotal trials, an independent photo panel rated 48% of men on finasteride as having increased hair growth at 12 months and 66% at 2 years, compared with 7% on placebo, and hair count stayed above baseline over 5 years.[15] Over 5 years, finasteride also cut the likelihood of developing further visible hair loss by 93% relative to placebo.[7]

Finasteride usually needs three months or more of daily use before benefit is seen.[15] The minoxidil 5% label says results may occur at 2 months with twice-daily use, but some men need at least 4 months.[16] In the finasteride trials, improvement was measured at both 1 and 2 years.[2] Photos taken at the same angle and lighting every few months are more reliable than day-to-day mirror checks for tracking real change.

To maintain results, yes. Finasteride and minoxidil are maintenance therapies, not one-time cures. Withdrawal of finasteride leads to reversal of its effect within 12 months,[15] and the minoxidil label says continued use is necessary to keep regrowth, or hair loss will begin again.[16]

In the first year of the hair loss trials, decreased libido occurred in 1.8 percent of men on finasteride versus 1.3 percent on placebo, erectile dysfunction in 1.3 versus 0.7 percent, and ejaculation disorder in 1.2 versus 0.7 percent. These resolved in men who stopped treatment because of them and in most who continued; the label also lists postmarketing reports of sexual dysfunction that continued after stopping.[15]

A subset of men report persistent sexual, neurological, or psychological symptoms after stopping finasteride. A 2020 review notes that the medical community has yet to recognize the syndrome and that many studies assessed adverse events incompletely, though its author concludes that finasteride induces persistent side effects in a subset of men.[14] The finasteride label lists postmarketing reports of sexual dysfunction that continued after discontinuation.[15] The cited sources do not establish how often this happens, and this uncertainty deserves a candid conversation before starting treatment.

Oral minoxidil lacks FDA approval for hair loss.[11] Its hypertension label, which covers much higher doses, carries a boxed warning about pericardial effusion and worsening angina.[17] At low doses for hair loss, a 1,404-patient multicenter study found hypertrichosis in 15.1% and infrequent systemic effects such as lightheadedness (1.7%), fluid retention (1.3%), and tachycardia (0.9%).[10] The main 5 mg study in men had no comparison group, so it cannot show whether oral minoxidil works better than topical, and its authors advise considering it only in healthy subjects.[4]

The dread shed is a temporary increase in shedding that can occur after starting minoxidil. Resting follicles shed and are usually soon replaced by new, thicker hairs in a new growth phase; the shedding reflects the hair-cycle synchronization that minoxidil induces.[12] It is not, by itself, a sign of worsening hair loss. The cited sources do not give a typical duration.

Transplantation is a reasonable option for men with stable, well-defined loss, typically Norwood IV and beyond, who have realistic expectations about donor supply. It works best alongside, not instead of, ongoing medical therapy, since native hair around a transplant remains susceptible to DHT-driven loss without continued treatment. Full results take 9 to 12 months to mature.

Generally, no. Biotin only helps in the rare case of an actual biotin deficiency. "Hair growth" shampoos and cosmetic serums may improve the hair shaft's appearance but do not address the follicle miniaturization driving androgenetic alopecia. Finasteride, minoxidil, and dutasteride have decades of trial evidence behind them and are also among the least expensive options on the market.

Yes. A licensed clinician can review medical history, including cardiovascular and psychiatric history, and prescribe oral finasteride, topical minoxidil, oral minoxidil, or dutasteride through a synchronous telehealth visit. Procedures such as PRP injections and hair transplantation require an in-person visit.

Finasteride inhibits type II 5-alpha reductase; dutasteride inhibits both type I and type II and suppresses DHT more in serum and scalp.[19] At 0.5 mg daily, dutasteride lowered median serum DHT by 90% after 2 weeks.[18] Dutasteride is approved for male androgenetic alopecia in Japan and South Korea,[19] but in the US it is indicated for benign prostatic hyperplasia[18] and is used off-label for hair loss; it has been studied in men who had an inadequate response to finasteride.[6] Its longer half-life (about 5 weeks versus about 4.5 hours for finasteride) means side effects may take longer to resolve after stopping.[19]

Patchy, well-circumscribed bald spots, scalp itching or scaling, rapid shedding over just a few weeks, scarring or shiny bald patches, and hair loss beginning before puberty are not typical of androgenetic alopecia and warrant evaluation for an alternative diagnosis such as alopecia areata, a scalp infection, telogen effluvium, or a scarring alopecia before defaulting to a male pattern hair loss treatment plan.

References

  1. Kanti V, Messenger A, Dobos G, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men - short version. J Eur Acad Dermatol Venereol. 2018;32(1):11-22. PubMed
  2. Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol. 1998;39(4 Pt 1):578-589. PubMed
  3. Chen L, Zhang J, Wang L, Wang H, Chen B. The Efficacy and Safety of Finasteride Combined with Topical Minoxidil for Androgenetic Alopecia: A Systematic Review and Meta-analysis. Aesthetic Plast Surg. 2020;44(3):962-970. PubMed
  4. Panchaprateep R, Lueangarun S. Efficacy and Safety of Oral Minoxidil 5 mg Once Daily in the Treatment of Male Patients with Androgenetic Alopecia: An Open-Label and Global Photographic Assessment. Dermatol Ther (Heidelb). 2020;10(6):1345-1357. Full text (PMC)
  5. Randolph M, Tosti A. Oral minoxidil treatment for hair loss: A review of efficacy and safety. J Am Acad Dermatol. 2021;84(3):737-746. PubMed
  6. Jung JY, Yeon JH, Choi JW, et al. Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride. Int J Dermatol. 2014;53(11):1351-1357. PubMed
  7. Kaufman KD, Rotonda J, Shah AK, Meehan AG. Long-term treatment with finasteride 1 mg decreases the likelihood of developing further visible hair loss in men with androgenetic alopecia (male pattern hair loss). Eur J Dermatol. 2008;18(4):400-406. PubMed
  8. Olsen EA, Dunlap FE, Funicella T, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002;47(3):377-385. PubMed
  9. Piraccini BM, Blume-Peytavi U, Scarci F, et al. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. J Eur Acad Dermatol Venereol. 2022;36(2):286-294. Full text (PMC)
  10. Vañó-Galván S, Pirmez R, Hermosa-Gelbard A, et al. Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients. J Am Acad Dermatol. 2021;84(6):1644-1651. PubMed
  11. Gupta AK, Talukder M, Shemer A, Piraccini BM, Tosti A. Low-Dose Oral Minoxidil for Alopecia: A Comprehensive Review. Skin Appendage Disord. 2023;9(6):423-437. PubMed
  12. Rossi A, Cantisani C, Melis L, et al. Minoxidil use in dermatology, side effects and recent patents. Recent Pat Inflamm Allergy Drug Discov. 2012;6(2):130-136. PubMed
  13. Trüeb RM. Finasteride treatment of patterned hair loss in normoandrogenic postmenopausal women. Dermatology. 2004;209(3):202-207. PubMed
  14. Traish AM. Post-finasteride syndrome: a surmountable challenge for clinicians. Fertil Steril. 2020;113(1):21-50. PubMed
  15. Organon LLC. PROPECIA (finasteride) tablets, film coated: prescribing information. Revised 8/2022. DailyMed, updated October 14, 2024. Accessed November 7, 2026. DailyMed
  16. Kenvue Brands LLC. Men's Rogaine Extra Strength Unscented (minoxidil topical solution 5%): Drug Facts label. DailyMed, updated September 6, 2024. Accessed November 7, 2026. DailyMed
  17. Pfizer. LONITEN (minoxidil tablets) prescribing information. FDA label dated January 13, 2015 (NDA 018154; product discontinued). Drugs@FDA. Accessed November 7, 2026. Drugs@FDA label (PDF)
  18. Waylis Therapeutics LLC. AVODART (dutasteride) capsules: prescribing information. Revised 10/2023. DailyMed, updated March 12, 2025. Accessed November 7, 2026. DailyMed
  19. Gupta AK, Talukder M, Williams G. Comparison of oral minoxidil, finasteride, and dutasteride for treating androgenetic alopecia. J Dermatolog Treat. 2022;33(7):2946-2962. PubMed
  20. Norwood OT. Male pattern baldness: classification and incidence. South Med J. 1975;68(11):1359-1365. PubMed

About the Author

Parth Bhavsar, MD

Dr. Bhavsar is a board-certified family medicine physician, founder of TeleDirectMD, and the physician editor of the TeleDirectMD Health Guides. He practices multi-state urgent care telemedicine with hospitalist experience.

Medically reviewed by Parth Bhavsar, MD. Last reviewed and fully rewritten July 18, 2026.